Zhitong Finance App News, HiCisco (002653.SZ) issued an announcement. The company recently received the HSK51155 “Drug Clinical Trial Approval Notice” issued by the State Drug Administration. HSK51155 is an oral small molecule analgesic with independent intellectual property rights independently developed by the company. It is clinically intended for migraine treatment. HSK51155 is expected to meet patients' pain control while reducing the occurrence of adverse reactions and avoiding the risk of addiction, bringing safer and more effective analgesia options for pain patients.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.